relapsed adult aml

Showing 1 - 14 of 14

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

Not yet recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Navitoclax Dose Level -1
  • +10 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023

Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)

Recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Venetoclax Oral Tablet
  • Augsburg, Germany
  • +11 more
Jan 11, 2023

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

Recruiting
  • Leukemia
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +9 more
Sep 9, 2022

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia Trial in United States

Recruiting
  • Relapsed Adult AML
  • +2 more
  • Specialty Palliative Care
  • Primary Palliative Care
  • Boston, Massachusetts
  • +3 more
Aug 12, 2022

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

Acute Myeloid Leukemia, Relapsed Adult AML Trial in United States (Lintuzumab-Ac225, Venetoclax, Spironolactone)

Recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • Los Angeles, California
  • +4 more
Feb 22, 2022

Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
Feb 22, 2022

AML/MDS, CMML, Relapse Trial in China, Spain, United States (LP-108, LP-108 and azacitidine)

Recruiting
  • AML/MDS
  • +5 more
  • Ann Arbor, Michigan
  • +7 more
Feb 14, 2022

Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 2, 2021

Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML Trial in Suzhou (CAHAG regimen, Placebo regimen)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • CAHAG regimen
  • Placebo regimen
  • Suzhou, Jiangsu, China
    The First Affliated Hospital of Soochow University
Oct 10, 2021

Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML Trial (ivosidenib (AG-120))

Approved for marketing
  • Acute Myeloid Leukemia
  • +2 more
  • ivosidenib (AG-120)
  • (no location specified)
Jul 20, 2018

Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL Trial in Montreal (GLIDE)

Unknown status
  • Hematologic Cancer
  • +8 more
  • GLIDE
  • Montreal, Quebec, Canada
    CIUSSS d l'Est-de-l'Île-de-Montréal
Dec 4, 2017